Immuno-Biological Laboratories Co (TSE:4570) EBIT: 円302 Mil (TTM As of Mar. 2026)


TSE:4570 Immuno-Biological Laboratories Co Ltd TSE:4570
59 GF Score
Price 円969.00
GF Value 円576.66
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Immuno-Biological Laboratories Co EBIT?

Immuno-Biological Laboratories Co TSE:4570 -2.02% 59 EBIT is 円302 Mil as of Mar. 2026. GuruFocus rates TSE:4570 with a GF Score™ of 59/100 and a GF Value™ of 円576.66 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Immuno-Biological Laboratories Co's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円151 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円302 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Immuno-Biological Laboratories Co's annualized ROC % for the quarter that ended in Mar. 2026 was 25.79%. Immuno-Biological Laboratories Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 45.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Immuno-Biological Laboratories Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.68%.

Immuno-Biological Laboratories Co  (TSE:4570) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Immuno-Biological Laboratories Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=278.316 * ( 1 - 0% )/( (1000.593 + 1158.037)/ 2 )
=278.316/1079.315
=25.79 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1965.744 - 9.817 - ( 955.334 - max(0, 269.861 - 1497.149+955.334))
=1000.593

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2155.121 - 7.612 - ( 989.472 - max(0, 276.194 - 1569.646+989.472))
=1158.037

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Immuno-Biological Laboratories Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=302.722/( ( (212.954 + max(439.415, 0)) + (213.171 + max(462.397, 0)) )/ 2 )
=302.722/( ( 652.369 + 675.568 )/ 2 )
=302.722/663.9685
=45.59 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(178.075 + 347.968 + 15.772) - (9.817 + 0 + 92.583)
=439.415

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(178.667 + 379.724 + 21.783) - (7.612 + 0 + 110.165)
=462.397

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Immuno-Biological Laboratories Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=301.895/8212.360
=3.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuno-Biological Laboratories Co EBIT Related Terms

Immuno-Biological Laboratories Co EBIT Historical Data

* Premium members only.

The historical data trend for Immuno-Biological Laboratories Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuno-Biological Laboratories Co EBIT Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -249.50 -279.54 125.77 211.12 301.90

Immuno-Biological Laboratories Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.37 64.83 146.29 150.53 151.36

TSE:4570 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Immuno-Biological Laboratories Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuno-Biological Laboratories Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Immuno-Biological Laboratories Co's EV-to-EBIT falls into.


TSE:4570
59GF Score
Immuno-Biological Laboratories Co Ltd TSE:4570
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immuno-Biological Laboratories Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円302 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円302 Mil mean?
Immuno-Biological Laboratories Co (TSE:4570) has a EBIT of 円302 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Immuno-Biological Laboratories Co.
Is Immuno-Biological Laboratories Co's EBIT too high?
Immuno-Biological Laboratories Co's current EBIT is 円302 Mil. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's EBIT compare to VRTX and REGN?
Immuno-Biological Laboratories Co's EBIT of 円302 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Immuno-Biological Laboratories Co. Immuno-Biological Laboratories Co's current EBIT is 円302 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円576.66, compared to a current price of 円969.00 — trading 68% above its estimated fair value. The current EBIT is 円302 Mil. Immuno-Biological Laboratories Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current EBIT is 円302 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?

Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued. The current stock price of 円969.00 is trading 68% above its estimated GF Value™ of 円576.66. GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.

Key valuation signals for TSE:4570:

  • EBIT: 円302 Mil
  • GF Value™: 円576.66 vs. price of 円969.00 (68% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immuno-Biological Laboratories Co Business Description

Address 1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
59GF Score

Get the complete analysis for TSE:4570

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円969.00
Price
円576.66
GF Value